Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage Over Inhibiting HGF/MET Signaling
Cancer Research - United States
doi 10.1158/0008-5472.can-15-0356
Full Text
Open PDFAbstract
Available in full text
Date
July 3, 2015
Authors
Publisher
American Association for Cancer Research (AACR)